Research ExplorerPublicationsHybrid electrospun chitosan-phospholipids nanofibers for tra...

Hybrid electrospun chitosan-phospholipids nanofibers for transdermal drug delivery

Standard

Hybrid electrospun chitosan-phospholipids nanofibers for transdermal drug delivery. / Mendes, Ana C; Gorzelanny, Christian; Halter, Natalia; Schneider, Stefan W; Chronakis, Ioannis S.

In: INT J PHARMACEUT, Vol. 510, No. 1, 20.08.2016, p. 48-56.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mendes, AC, Gorzelanny, C, Halter, N, Schneider, SW & Chronakis, IS 2016, 'Hybrid electrospun chitosan-phospholipids nanofibers for transdermal drug delivery', INT J PHARMACEUT, vol. 510, no. 1, pp. 48-56. https://doi.org/10.1016/j.ijpharm.2016.06.016

APA

Mendes, A. C., Gorzelanny, C., Halter, N., Schneider, S. W., & Chronakis, I. S. (2016). Hybrid electrospun chitosan-phospholipids nanofibers for transdermal drug delivery. INT J PHARMACEUT, 510(1), 48-56. https://doi.org/10.1016/j.ijpharm.2016.06.016

Vancouver

Mendes AC, Gorzelanny C, Halter N, Schneider SW, Chronakis IS. Hybrid electrospun chitosan-phospholipids nanofibers for transdermal drug delivery. INT J PHARMACEUT. 2016 Aug 20;510(1):48-56. https://doi.org/10.1016/j.ijpharm.2016.06.016

Bibtex

@article{f9e234c6945c4636b29c20647206bbe1,
title = "Hybrid electrospun chitosan-phospholipids nanofibers for transdermal drug delivery",
abstract = "Chitosan (Ch) polysaccharide was mixed with phospholipids (P) to generate electrospun hybrid nanofibers intended to be used as platforms for transdermal drug delivery. Ch/P nanofibers exibithed average diameters ranging from 248±94nm to 600±201nm, depending on the amount of phospholipids used. Fourier Transformed Infra-Red (FTIR) spectroscopy and Dynamic Light Scattering (DLS) data suggested the occurrence of electrostatic interactions between amine groups of chitosan with the phospholipid counterparts. The nanofibers were shown to be stable for at least 7days in Phosphate Buffer Saline (PBS) solution. Cytotoxicity studies (WST-1 and LDH assays) demonstrated that the hybrid nanofibers have suitable biocompatibility. Fluorescence microscopy, also suggested that L929 cells seeded on top of the CH/P hybrid have similar metabolic activity comparatively to the cells seeded on tissue culture plate (control). The release of curcumin, diclofenac and vitamin B12, as model drugs, from Ch/P hybrid nanofibers was investigated, demonstrating their potential utilization as a transdermal drug delivery system.",
keywords = "Journal Article",
author = "Mendes, {Ana C} and Christian Gorzelanny and Natalia Halter and Schneider, {Stefan W} and Chronakis, {Ioannis S}",
note = "Copyright {\textcopyright} 2016 Elsevier B.V. All rights reserved.",
year = "2016",
month = aug,
day = "20",
doi = "10.1016/j.ijpharm.2016.06.016",
language = "English",
volume = "510",
pages = "48--56",
journal = "INT J PHARMACEUT",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Hybrid electrospun chitosan-phospholipids nanofibers for transdermal drug delivery

AU - Mendes, Ana C

AU - Gorzelanny, Christian

AU - Halter, Natalia

AU - Schneider, Stefan W

AU - Chronakis, Ioannis S

N1 - Copyright © 2016 Elsevier B.V. All rights reserved.

PY - 2016/8/20

Y1 - 2016/8/20

N2 - Chitosan (Ch) polysaccharide was mixed with phospholipids (P) to generate electrospun hybrid nanofibers intended to be used as platforms for transdermal drug delivery. Ch/P nanofibers exibithed average diameters ranging from 248±94nm to 600±201nm, depending on the amount of phospholipids used. Fourier Transformed Infra-Red (FTIR) spectroscopy and Dynamic Light Scattering (DLS) data suggested the occurrence of electrostatic interactions between amine groups of chitosan with the phospholipid counterparts. The nanofibers were shown to be stable for at least 7days in Phosphate Buffer Saline (PBS) solution. Cytotoxicity studies (WST-1 and LDH assays) demonstrated that the hybrid nanofibers have suitable biocompatibility. Fluorescence microscopy, also suggested that L929 cells seeded on top of the CH/P hybrid have similar metabolic activity comparatively to the cells seeded on tissue culture plate (control). The release of curcumin, diclofenac and vitamin B12, as model drugs, from Ch/P hybrid nanofibers was investigated, demonstrating their potential utilization as a transdermal drug delivery system.

AB - Chitosan (Ch) polysaccharide was mixed with phospholipids (P) to generate electrospun hybrid nanofibers intended to be used as platforms for transdermal drug delivery. Ch/P nanofibers exibithed average diameters ranging from 248±94nm to 600±201nm, depending on the amount of phospholipids used. Fourier Transformed Infra-Red (FTIR) spectroscopy and Dynamic Light Scattering (DLS) data suggested the occurrence of electrostatic interactions between amine groups of chitosan with the phospholipid counterparts. The nanofibers were shown to be stable for at least 7days in Phosphate Buffer Saline (PBS) solution. Cytotoxicity studies (WST-1 and LDH assays) demonstrated that the hybrid nanofibers have suitable biocompatibility. Fluorescence microscopy, also suggested that L929 cells seeded on top of the CH/P hybrid have similar metabolic activity comparatively to the cells seeded on tissue culture plate (control). The release of curcumin, diclofenac and vitamin B12, as model drugs, from Ch/P hybrid nanofibers was investigated, demonstrating their potential utilization as a transdermal drug delivery system.

KW - Journal Article

U2 - 10.1016/j.ijpharm.2016.06.016

DO - 10.1016/j.ijpharm.2016.06.016

M3 - SCORING: Journal article

C2 - 27286632

VL - 510

SP - 48

EP - 56

JO - INT J PHARMACEUT

JF - INT J PHARMACEUT

SN - 0378-5173

IS - 1

ER -